This case-based program is designed to educate healthcare providers on the optimal management of patients with ER+/HER2– MBC, with the goal of improving patient outcomes including quality of life and survival.
This activity is designed to educate medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, and other allied health professionals on the optimal management of metastatic breast cancer.
This case-based program is designed to educate these healthcare providers on the optimal management of patients with ER+/HER2 MBC, with the goal of improving patient outcomes including quality of life and survival.
To view this CME activity, click here >>>
Upon completing this activity as designed, participants should be able to:
Target Audience:Medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, and other allied health professionals.
Type of Activity:Knowledge
Release date:April 30, 2015
Expiration date:April 30, 2016
Estimated time to complete activity:2 hours
To view this CME activity, click here >>>
Featuring Consultations With
Joyce O'Shaughnessy, MD
Chair, Breast Cancer Research
Baylor-Sammons Cancer Center
Texas Oncology, US Oncology
Dallas, TX
Linda T. Vahdat, MD
Professor of Medicine
Director of the Breast Cancer Research Program,
Chief of the Solid Tumor Service
Weill Cornell Medical College
New York, NY
With Community Oncologist's Perspective by
Hussein Ali-Ahmad, MD
Clinical Assistant Professor of Oncology
Roswell Park Cancer Institute
Jamestown, NY
Sigrid Eckhardt
Hitt Medical Writing, LLC
This activity is supported by an educational grant from Eisai.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More